Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients.
Rannakoe J
Lehloenya
;
Sipho
Dlamini
;
Rudzani
Muloiwa
;
Betty
Kakande
;
Mzudumile R
Ngwanya
;
Gail
Todd
;
Keertan
Dheda
;
(2016)
Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients.
OPEN FORUM INFECTIOUS DISEASES, 3 (3).
ofw130-.
ISSN 2328-8957
DOI: 10.1093/ofid/ofw130
Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.
Item Type | Article |
---|---|
Elements ID | 132263 |
Date Deposited | 21 Jan 2020 09:46 |
ORCID: https://orcid.org/0000-0001-7709-5341